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Purpose: To assess the impact of an educational intervention on pharmacists’ medication counselling 
practice, and evaluate the reliability of an instrument to assess medication counselling in a psychiatric 
setting. 
Methods: The study was undertaken on a sample of 297 psychiatric patients. Pre- and post-intervention 
surveys were conducted immediately after the patients had been attended to at the hospital’s outpatient 
pharmacy, using a self-administered questionnaire, comprising 4 components. Internal consistency of 
the questionnaire was computed using Cronbach’s alpha. Differences between means or proportions of 
variables were evaluated using Student’s t-test or Chi-square test, as appropriate.  
Results: The study achieved a response rate of 89 and 92 % for pre– and post–intervention surveys, 
respectively. Cronbach’s alpha reliability of the instrument was found to be 0.74. The mean values for 
the different components evaluated during the pre- and post–intervention surveys were: Needs 
assessment, 1.89± 0.76 and 2.58 ± 0.61; Precaution and warning, 1.50 ± 0.67 and 2.15 ± 0.63; 
Managing therapy, 1.87 ± 0.89 and 2.46 ± 0.78, and Communication, 2.23 ± 0.77 and 2.69 ± 0.62, 
respectively. The post–intervention results were significantly higher in all the components (p < 0.05). 
Conclusion: The educational intervention provided for pharmacists resulted in an improvement in 
patient counselling. The survey instrument achieved a fairly satisfactory reliability result in a psychiatric 
setting. Efforts to sustain this intervention are recommended. 
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INTRODUCTION 
 
Approximately 450 million persons in the 
world are said to be suffering from mental or 
neurological disorders or from psychological 
problems such as those related to alcohol 
and drug abuse [1]. Among the several 
treatment options available for mental 
illnesses, pharmacotherapy plays a central 
role. In clinical practice, the use of drugs with 
demonstrated efficacy in psychiatric disorders 
has become widespread since the mid - 
1950s[2]. However, among the greatest 
challenges in pharmacotherapy of mental 
illnesses, medication adherence, anti-
psychotic medication availability, cost and 
adverse effects, including medication errors 
have the greatest potential to compromise 
therapeutic outcomes [3,4].  
 
Despite efforts at developing newer 
antipsychotic medications with broader 
efficacy and improved side effect profile, the 
issue of adherence and accessibility have 
continued to compromise patients’ 
therapeutic outcomes[5]. In particular, 
adherence remains a major concern in 
pharmacotherapy of mental illnesses, 
especially among schizophrenic patients. 
Non-adherence with antipsychotic 
medications has been shown to be a robust 
predictor of relapse, hospitalizations, and 
poorer long-term functional outcomes, 
including greater likelihood of being arrested, 
of being violent, and of becoming a victim of 
violent crimes [6].
             
 
 
However, studies have shown that services 
provided by pharmacists such as medication 
counselling, therapeutic monitoring and 
medication supply etc, can potentially 
optimize the use of medications for mentally 
ill patients [7,8]. For example, Canales et al 
[8] reported that the provision of clinical 
pharmacy services to inpatients in an acute 
care psychiatric facility was associated with 
improvements in rating-scale scores for 
clinical response and for drug-induced 
extrapyramidal symptoms. Although, 
pharmacists believe that they are the health 
care professionals most qualified to counsel 
patients on medications [8,9], patient 
medication counselling by the pharmacist 
may be limited by factors such as poor 
pharmacist-patient interaction during clinical 
encounters, pharmacists’ lack of time, 
inadequate staff etc [9, 10], especially in a 
psychiatric setting.
 
 Indeed, Owusu-Daar et al 
(2010) reported that community and hospital 
pharmacists in Ghana provide minimal 
mental health care services to their patients 
[11]. However, it has consistently been 
advocated that pharmacists become more 
patient-centered in the provision of 
pharmaceutical care in order to meet their 
professional responsibilities [12]. The pivotal 
role of pharmacists in reducing the incidence 
of both medication-related errors and drug-
related illness in general is noted in literature 
[13].  Patient counseling is an important part 
of pharmacists’ professional services [14]. By 
providing information to consumers with 
prescriptions, pharmacists appear to be 
fulfilling the minimum practice standards [15]. 
The objectives of this study, therefore, were 
to evaluate patient counselling provided by 
pharmacists for psychiatric patients, assess 
the impact of an educational intervention on 
pharmacists’ medication counselling 
behaviour, and evaluate the reliability of an 
instrument to assess medication counselling 






The study was carried out at the outpatient 
section of the Pharmacy Department, 
Psychiatric Hospital, Uselu, Benin City, 
Nigeria. The study site is a tertiary hospital, 
which serves as a referral center for patients 
from Edo State (of which Benin City is the 
capital) and neighboring states. It also serves 
as a teaching hospital for the training of 
undergraduate and postgraduate health 
professionals in the state. A majority of 
patients attending this healthcare facility have 
mood disorders or schizophrenia. 
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Data collection process 
 
Approval for the study was obtained from the 
hospital management prior to the 
commencement of the research. Data 
collection was carried out using a self-
administered questionnaire, which was 
designed by the investigators from review of 
literature, informal discussion with some 
patients and health professional, and 
personal professional experiences. One of 
the investigators, EFOE, has been actively 
involved in the supervision of clinical 
clerkship of pharmacy students in psychiatry 
for several years and was also highly 
instrumental to the development of 
pharmaceutical care model in this setting.  In 
particular, items in the questionnaire were 
developed using the United States 
Pharmacopoeia (USP) Medication 
Counselling Behaviour Guidelines 
(MCBG)[16] as a guide. The USP MCBG has 
been used to assess patient medication 
counselling by pharmacists, and it was found 
to be a flexible tool, which can be modified in 
several ways without threatening its validity 
and reliability [16].   
 
The developed questionnaire was validated 
by first conducting a pilot-test on a sample of 
25 patients. Thereafter, slight modification 
was further carried out on it, based on the 
results from the pilot test. The final version of 
the questionnaire used for the study had two 
parts. The first part was designed to collect 
socio-demographic information from the 
respondents. The second part collected 
information on pharmacist’s medication 
counselling behaviour. There were 34 items 
with 3-point response scale, 3 to 1 (highest to 
lowest), in the second part of the 
questionnaire, which covered four 
components (needs assessment, precaution 
and warnings, management of treatment, and 
communication).  These components were 
thought to be relevant in pharmacists’ 
medication counselling. The same 
questionnaire was administered at both pre - 




Psychiatric out-patients who were mentally 
stable, as judged by the clinicians’ 
assessment, and were able to read and write 
expressions in English Language participated 
in the study. Patients were recruited 
consecutively immediately after they had 




Three registered and 8 intern pharmacists 
who were routinely involved in outpatient 
pharmacy services in the hospital, the 
investigators, and 3 pharmacy students 
participated in this session. Prior to the 
intervention, data on pre-intervention survey 
were analyzed, and the results were made 
available for discussion. The intervention 
commenced with 40 minutes of a lecture 
delivered by the investigators. The lecture 
was based on the USP MCBG[16],
 
review 
from other literatures, and clinical experience 
in psychiatric setting. This was followed by 
two hours of interactive session among the 
participants on the same day. In addition, 
lecture materials on patient counselling were 
distributed to the participants, and the 
hospital pharmacists were encouraged to 
continue discussion on the topic in next 
couple of days that followed, prior to the post-




Data were entered into Microsoft Excel 
Spreadsheet, and cross checked for 
accuracy. Thereafter, the data were loaded 
into SPSS version 11.0 or Graph Pad Instat® 
version 2.05a for further analysis. Internal 
consistency of the questionnaire was 
determined by computing Cronbach’s alpha, 
while Factor analysis was performed using 
Principal Components analysis with Varimax 
rotation. Descriptive statistics on sample 
characteristics and questionnaire items were 
computed, including means, standard 
deviation, and frequency distributions. 
Differences between means were calculated 
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using Student’s t – test, while the differences 
between proportions were determined by 
means of Chi - square test.  P-values less 




A total number of 200 patients were 
approached during the pre-intervention stage. 
Of this number, 15 were excluded because 
they were considered not mentally stable to 
give reliable responses, based on clinicians’ 
judgment. Of those who were selected, 7 
refused to participate in the study. The 178 
respondents who completed the 
questionnaire were used for the pre-
intervention analysis, giving a response rate 
of 89 % (178/200). Similarly, the response 
rate for the post-intervention was found to be 
92 % (119/130).  
 
A majority of the respondents at the pre-
intervention stage were 30 to 39 years old 
(30%), male (54%), single (50%), civil 
servants (28%), and 50% had secondary 
education.  On the other hand, a majority of 
the respondents at the post-intervention 
survey were 40 to 49 years old (27%), male 
(56%), married (74%), unemployed (35%), 
and had post-secondary education (49%). 
However, there were no significant 
differences in the socio-demographic profiles 
of the respondents at both pre- and post – 
intervention survey, except for marital status 
and occupation (Table 1). 
 
The Cronbach’s alpha for all the 34 items 
was found to be 0.74. The Factor loading for 
the four sub-scales ranged from 0.49 to 0.73 
(Component 1), 0.51 to 0.98 (Component 2), 
0.45 to 0.77 (Component 3), and 0.22 to 0.67 
(Component 4). 
 
Table 1:   Socio-demographics of the respondents 
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The mean (± s.d) values of pre- and post – 
intervention scores for the four components 
were found to be 1.89 ± 0.76 and 2.58 ± 0.61 
(Component 1), 1.50 ± 0.67 and 2.15 ± 0.63 
(Component 2), 1.87 ± 0.89 and 2.46 ± 0.78 
(Component 3), and 2.23 ± 0.77 and 2.69 ± 
0.62 (Component 4), respectively. There 
were significant differences between the pre 
– and post – intervention scores, with the 
post–intervention results significantly higher 
in all the components (p < 0.05) (Tables 2 - 
5).   
 




Mean score ±SD 
Post-intervention 
(n=119) 
Mean score ±SD 
P-value* 
1. Did your pharmacist introduce 
himself as a health care professional 
(or pharmacist) before he discussed 
with you?                                                                                         
 
2. Did your pharmacist verify your 
name, to find out if you were the 
owner of the prescription or case file 
before you?                                                                                  
 
3. Did your pharmacist provide privacy 
during his discussion with you?                               
 
4. Did your pharmacist review your 
prescription / case note prior to his 
discussion with you?                                                                                                                               
 
5. Did your pharmacist explain the 
purpose of the discussion with you?             
 
6. Did your pharmacist try to find out if 
you were on any other medications at 
the moment?                                                                                                                         
  
7. Did your pharmacists present facts 
and concepts about your medications 
in a logical order?                                                                                                                            
 
8. Did your pharmacist find out if you 
have history of any chronic diseases 
like diabetes or hypertension in your 
family?                                                                             
 
9. Did your pharmacist find out if you 
have any drug or food allergies?  
 
 















































































































Offor & Enato  
Trop J Pharm Res, August 2011;10 (4): 512 




Mean score ±SD 
Post-intervention 
(n=119) 
Mean score ±SD 
P-value 
10. Did your pharmacist explore any 
potential problems associated with 
your medications, (e.g. 
affordability)?                                                                                                           
 
11. Did your pharmacist discuss 
any significant side effects of your 
medications with You?                                                                                                                                 
 
12. Did your pharmacist warn you 
not to take any drug, alcohol or 
herbal products concurrently with 
your medications?                                                                                   
 
13. Did your pharmacist discuss 
any drug-drug, drug-disease or 
drug-food interactions of your 
medications with you?                                                                                             
 
14. Did your pharmacist explain to 
you in precise terms what to do 
when you miss a dose?     
 
15. Did your pharmacist tell you the 
activities to avoid when you are on 
your medications?     
 
16. Did your pharmacist help you 
generate solutions to some of the 
potential problems of your 
medication?                                                                                                   
 
17.  Did your pharmacist tell you 
how to prevent and/ or manage side 
effects of your drugs if they occur? 
 














































































































The instrument used for the evaluation 
demonstrated a fairly satisfactory level of 
reliability, with alpha of 0.74, indicating that 
with further refinement, particularly at the 
subscale level, the questionnaire could 
become useful for routine assessment of 
pharmacists’ medication counselling 
practices in a psychiatric setting. A minimum 
value of 0.7 is needed to ascertain the 
reliability of the research instrument [17].  In 
all the components of medication counselling, 
patients rated pharmacists higher during 
post-intervention phase when compared to 
pre-intervention survey, an indication that the 
educational session provided for the 
pharmacists was effective in modifying their 
counselling behaviours. This, in addition, to 
the enthusiasm shown by the participating  
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Mean score ±SD 
Post-intervention (n=119) 
Mean score ±SD 
P-value 
18. Did your pharmacist discuss the 
storage conditions and other 
ancillary instructions of your 
medications with you?                                                                                                
 
19. Did your pharmacist tell you how 
long it would take before your drugs 
start showing effects?                                                                                                                            
 
20. Did your pharmacist tell you 
when to come back to refill your 
medications?                     
 
21. Did your pharmacist emphasize 
on the need for you to complete 
your medications?     
 
22. Did your pharmacist assist you 
in developing a plan to incorporate 
your medication regimen into your 
daily routine?                                                                                     
 
23. Did your pharmacist explain 
how, when and how long you would 
use your medications?  
 
24. Did your pharmacist give you an 
opportunity to ask questions or 
express your opinions?  
 
25. Did your pharmacist try to find 
out if you understand the advice he 
gave you by asking you to repeat 
them?                                                                                                          
 
26. Did your pharmacist ask you if 
you needed additional information? 
                                 
27. Did your pharmacist maintain 
control and direction of your 
conversations without being 
distracted by phone calls, TV, radio 
or other staff members?                                                
 
28. Did your pharmacist ask you 
good open-ended questions (i.e. 
questions beginning with ‘why’, 
‘how’, ‘when’, ‘where’?                                                                                              
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Mean score ±SD 
Post-intervention 
(n=119) 
Mean score ±SD 
P-value 
29. Did your pharmacist provide you 
with accurate information?                                          
 
30. Did your pharmacist tell you the 
name and indications of your 
medications?             
 
31. Did your pharmacist maintain the 
following communication skills: 
 
(i).Good eye contacts?                                                                                                   
 
(ii). Audible voice, tone and good 
pace?                                                                          
(iii). Good posture and gestures?                                                                                      
 
(iv). Adequate space between him 
and you?                                                                      































































pharmacists and the willingness to 
immediately implement the knowledge and 
skills acquired during the educational session 
is laudable. This finding is similar to a report 
of an earlier initiative in the locality, where 
after extensive training on pharmaceutical 
care, the pharmacists felt highly motivated 
toward its implementation in their health  
facility [18]. 
 
Though psychiatry clinical pharmacy practice 
and research is limited worldwide, and almost 
completely not existent in Nigeria; however, 
we believe that huge opportunities abound for 
the practitioners. For example, psychiatric 
pharmacists have the potential to ensure 
optimal pharmacotherapeutic outcomes for 
their patients [10, 11, 19],
 
 in addition to 
providing patient counselling and ensuring 
prompt access to good quality medications.  
Through research and training for the 
practitioners, psychiatric pharmacy practice in 
the country could be developed to a level 
comparable to what is obtainable in the 
developed countries. Psychiatric pharmacy 
addresses the pharmaceutical care of 
patients with psychiatric-related illnesses 
[20].  
 
To the best of our knowledge, this study 
appears to be first of its kind in the country, 
addressing an almost neglected and often 
completely unmentioned area of pharmacy 
practice. We believe, though it could be 
argued otherwise, that irrespective of the 
nature of the psychiatric illness itself, patients 
should have the opportunity of evaluating the 
quality of care that they receive. Nabeel et al, 
in a similar study in Kuwait, reported that 
depressed patients expressed their eager to 
receive education about medications from 
pharmacists [21].  
 
Limitations of study 
 
Nonetheless, we recommend that data from 
the study should be treated as they apply to 
psychiatric patients whose disorders are 
completely different from those of other 
patient populations. In addition, some 
limitations of this study are worth mentioning. 
The research instrument, which was not 
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validated against standard generic instrument 
such as SF-36. Secondly, the use of a 3-point 
response scale may have impacted 
negatively on the internal consistency of the 
questionnaire items.  Finally, one cannot say 
with certainty the level of reliability of 
information provided by the psychiatric 
patients.  
 
However, these limitations are not likely to 
have greatly affected the overall result, as the 
same instrument was used for both pre- and 
post intervention studies on the respondents, 
which were drawn from the same population.  
Furthermore, we ensured that only patients 
on chronic antipsychotic drug therapy with 
significant stability of their conditions were 





The research instrument achieved a fairly 
satisfactory reliability result in a psychiatric 
setting. The educational intervention provided 
for pharmacists resulted in an improvement in 
patient counseling for psychiatric patients. 
Efforts should be made to ensure training and 
retraining of pharmacists in psychiatric 
pharmacy practice in Nigeria. 
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